- Health Canada has approved Cysklar (cysteamine ophthalmic solution), developed by Leadiant Biosciences, for treating corneal cystine crystal accumulation in patients with cystinosis
- Cystinosis is a rare, multi-system genetic disorder causing cystine crystal buildup across organs, including the eyes, often leading to vision complications
- Cysklar is a topical ophthalmic solution designed as an easy-to-use treatment option for managing corneal crystals in affected patients
- The approval marks a key milestone for the cystinosis community in Canada, with Leadiant planning to provide further updates on product availability
Takeaways:
Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ophthalmology footprint while addressing a clear unmet need in vision preservation.
For your newsletter, you could frame it as: this approval adds another specialized tool to the cystinosis toolkit and may improve long‑term ocular outcomes and treatment adherence, with Leadiant expected to clarify pricing and availability details as it prepares launch.
Source: Businesswire
